Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 286

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Phase 2 Trial of Ibudilast in Progressive Multiple Sclerosis

Open access
Fox, Robert J., Coffey, Christopher S., Conwit, Robin, Cudkowicz, Merit E., Gleason, Trevis, Goodman, Andrew, Klawiter, Eric C., Matsuda, Kazuko, McGovern, Michelle, Naismith, Robert T., Ashokkumar, Akshata, Barnes, Janel, Ecklund, Dixie, Klingner, Elizabeth, Koepp, Maxine, Long, Jeffrey D., Natarajan, Sneha, Thornell, Brenda, Yankey, Jon, Bermel, Robert A., Debbins, Josef P., Huang, Xuemei, Jagodnik, Patricia, Lowe, Mark J., Nakamura, Kunio, Narayanan, Sridar, Sakaie, Ken E., Thoomukuntla, Bhaskar, Zhou, Xiaopeng, Krieger, Stephen, Alvarez, Enrique, Apperson, Michelle, Bashir, Khurram, Cohen, Bruce A., Coyle, Patricia K., Delgado, Silvia, Dewitt, L. Dana, Flores, Angela, Giesser, Barbara S., Goldman, Myla D., Jubelt, Burk, Lava, Neil, Lynch, Sharon G., Moses, Harold, Ontaneda, Daniel, Perumal, Jai S., Racke, Michael, Repovic, Pavle, Riley, Claire S., Severson, Christopher, Shinnar, Shlomo, Suski, Valerie, Weinstock-Guttman, Bianca, Yadav, Vijayshree, Zabeti, Aram · 2018 · New England Journal of Medicine

Abstract

BACKGROUND: There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 and can cross the blood-brain barrier, with potential salutary effects in progressive multiple sclerosis. METHODS: We enrolled patients with primary or secondary progressive multiple sclerosis in a phase 2 randomized trial of oral ibudilast (≤100 mg daily) or placebo for 96 weeks. The primary efficacy end point was the rate of brain atrophy, as measured by the brain parenchymal fraction (brain size relative to the volume of the outer surface contour of the brain). Major secondary end points included the change in the pyramidal tracts on diffusion tensor imaging, the magnetization transfer ratio in normal-appearing brain tissue, the thickness of the retinal nerve-fiber layer, and cortical atrophy, all measures of tissue damage in multiple sclerosis. RESULTS: Of 255 patients who underwent randomization, 129 were assigned to ibudilast and 126 to placebo. A total of 53% of the patients in the ibudilast group and 52% of those in the placebo group had primary progressive disease; the others had secondary progressive disease. The rate of change in the brain parenchymal fraction was -0.0010 per year with ibudilast and -0.0019 per year with placebo (difference, 0.0009; 95% confidence interval, 0.00004 to 0.0017; P=0.04), which represents approximately 2.5 ml less brain-tissue loss with ibudilast over a period of 96 weeks. Adverse events with ibudilast included gastrointestinal symptoms, headache, and depression. CONCLUSIONS: In a phase 2 trial involving patients with progressive multiple sclerosis, ibudilast was associated with slower progression of brain atrophy than placebo but was associated with higher rates of gastrointestinal side effects, headache, and depression. (Funded by the National Institute of Neurological Disorders and Stroke and others; NN102/SPRINT-MS ClinicalTrials.gov number, NCT01982942 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1803583

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 286

Metadata

Authors
Fox, R. J., Coffey, C. S., Conwit, R., Cudkowicz, M. E., Gleason, T., Goodman, A., Klawiter, E. C., Matsuda, K., McGovern, M., Naismith, R. T., Ashokkumar, A., Barnes, J., Ecklund, D., Klingner, E., Koepp, M., Long, J. D., Natarajan, S., Thornell, B., Yankey, J., Bermel, R. A., Debbins, J. P., Huang, X., Jagodnik, P., Lowe, M. J., Nakamura, K., Narayanan, S., Sakaie, K. E., Thoomukuntla, B., Zhou, X., Krieger, S., Alvarez, E., Apperson, M., Bashir, K., Cohen, B. A., Coyle, P. K., Delgado, S., Dewitt, L. D., Flores, A., Giesser, B. S., Goldman, M. D., Jubelt, B., Lava, N., Lynch, S. G., Moses, H., Ontaneda, D., Perumal, J. S., Racke, M., Repovic, P., Riley, C. S., Severson, C., Shinnar, S., Suski, V., Weinstock-Guttman, B., Yadav, V., & Zabeti, A.
Venue
New England Journal of Medicine
Published
2018-08-30
Volume
379
Issue
9
Pages
846-855
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2888865579
Cited by
286
References
29
FWCI
22.34
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.